Events

SAN DIEGO–(BUSINESS WIRE)–Trefoil Therapeutics, a clinical-stage biotechnology company focused on restoring sight to people with corneal diseases, today announced multiple presentations providing evidence for clinical and preclinical efficacy of the company’s investigational medicine TTHX1114 for improving visual outcomes and protection

Trefoil Therapeutics presents accelerated healing of corneal endothelial lesions by engineered fibroblast growth factor at ARVO 2020.